| Literature DB >> 26723915 |
Miłosz Regulski1, Katarzyna Regulska2, Wiesław Prukała3, Hanna Piotrowska1, Beata Stanisz4, Marek Murias5.
Abstract
Cyclooxygenase-2 (COX-2) inhibitors are common anti-inflammatory drugs with pleiotropic, endogenous actions that could be useful in the management of breast cancer. Here, we provide a complete understanding of the biochemistry of COX-2 and discuss the various molecular mechanisms behind its increased expression in breast cancer. We also analyze the possible mechanisms responsible for the anticancer effect of COX-2 inhibitors and provide an overview of the available preclinical and clinical data on the use of COX-2 inhibitors in breast cancer. Finally, we describe a mathematical model of the relation between the structure and biological potency of promising new COX-2 inhibitors (trans-stilbenes) using a 2D quantitative structure-activity relationship (QSAR) technique.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26723915 DOI: 10.1016/j.drudis.2015.12.003
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851